title: Neurologic indications for therapeutic plasma exchange: 2011 update.
abstract: Neurologists commonly use therapeutic plasma exchange (TPE) to treat a number of conditions. This concise review examines the most common neurologic indications for TPE. It focuses on Guillain-Barre' syndrome and myasthenia gravis and also the role of TPE in chronic inflammatory demyelinating polyneuropathy, Lambert-Eaton syndrome, multiple sclerosis, neuromyelitis optica, paraproteinemic polyneuropathy, Sydenham's chorea, and natalizumab-associated progressive multifocal leukoencephalopathy (PML). As with any treatment, the proven efficacy, cost, side effects, and availability must be considered before initiation of therapy.
authors.affiliation: Department of Neurology, The University of Virginia, Charlottesville, Virginia, USA.
authors.forename: Kelly
authors.initials: K
authors.lastname: Gwathmey
authors.forename: Rasheed A
authors.initials: RA
authors.lastname: Balogun
authors.forename: Ted
authors.initials: T
authors.lastname: Burns
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D002819:Chorea / Q000628:therapy; D020275:Guillain-Barre Syndrome / Q000628:therapy; D006801:Humans; D015624:Lambert-Eaton Myasthenic Syndrome / Q000628:therapy; D007968:Leukoencephalopathy, Progressive Multifocal / Q000209:etiology / Q000628:therapy; D009103:Multiple Sclerosis / Q000628:therapy; D009157:Myasthenia Gravis / Q000628:therapy; D000069442:Natalizumab; D009422:Nervous System Diseases / Q000628:therapy*; D009471:Neuromyelitis Optica / Q000628:therapy; D010265:Paraproteinemias / Q000628:therapy; D010951:Plasma Exchange / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D011115:Polyneuropathies / Q000628:therapy; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000628:therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab